Saul Priceman, Ph.D., is an assistant research professor in the T Cell Immunotherapy Program at City of Hope and a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate, and pancreatic cancer.
Dr. Priceman received his B.S. in microbiology at the University of California, Santa Barbara, and his Ph.D. in molecular and medical pharmacology at the University of California, Los Angeles.
Dr. Priceman is a principal investigator on a Prostate Cancer Foundation Young Investigator award, a co-principal investigator on a Prostate Cancer Foundation Challenge Award, and a principal investigator on a National Comprehensive Cancer Network Young Investigator award, leading the development of HER2-specific CAR-T therapy for metastatic breast cancers, and working with his team optimizing new CAR-T cell therapies for various other solid cancers.
Dr. Priceman is deeply committed to rapidly advancing potentially paradigm-shifting immunotherapy on behalf of patients with cancer, in part because of personal experiences with family and friends who have struggled with the disease. His overarching goal is to develop a range of effective immunotherapies for solid cancers, based on the powerful CAR-T cell platform, with the knowledge that any single therapy will not likely provide durable responses in advanced disease.